In the BioHarmony Drug Report Database
Lanreotide
Somatuline Depot (lanreotide) is a protein pharmaceutical. Lanreotide was first approved as Somatuline Depot on 2007-08-30. It is used to treat acromegaly and neuroendocrine tumors in the USA. The pharmaceutical is active against somatostatin receptor type 2 and somatostatin receptor type 5. In addition, it is known to target somatostatin receptor type 3.
Trade Name
|
Somatuline Depot |
|---|---|
Common Name
|
lanreotide |
ChEMBL ID
|
CHEMBL1201185 |
Indication
|
acromegaly, neuroendocrine tumors |
Drug Class
|
Peptides: inhibition of growth hormone release |
Image (chem structure or protein)